Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market

The total incident population of Non Small Cell Lung Cancer in the seven major markets was 484,726 in 2017. The incident cases of EGFR mutation in the United States in 2017 was 37,370.
In 2017, it was observed that the incident population of EGFR-NSCLC in the United States contributed around 34% of the total population of EGFR mutated NSCLC in the 7MM.

The total market size of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market in the 7MM was found to be USD 1,893 Million in 2017, which is expected to increase during the forecast period 2017-2030.

The key companies in the EGFR-NSCLC market include Novartis, Yuhan Pharmaceutical, Janssen Pharmaceutica, Takeda, Pfizer, AstraZeneca and many others.

For more detailed information on EGFR-NSCLC market visit: https://www.delveinsight.com/report-store/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market